WebCingulate currently has two (2) product candidates, CTX-1301 and CTX-1302, that are being developed to serve the approximate $18 billion annual U.S. ADHD market. A third product candidate, CTX-2103, is being developed to serve the roughly $5 billion U.S. … 23 Feb 2024 Cingulate Announces Positive Top-Line Results from Fed/Fast Study … Pipeline Overview. Cingulate® completed a proof-of-concept trial in human subjects … Cingulate Inc. 1901 W 47th Place Kansas City, KS 66205 (913) 942-2300 … Shane J. Schaffer, PharmD is a Co-Founder of Cingulate Therapeutics and … About Cingulate®. Cingulate® (CTx®)is a Phase 3 clinical stage … Mr. Gallagher is a Co-Founder of Cingulate Therapeutics and serves as a member …
Cingulate Inc. (CING) - Yahoo Finance
WebApr 12, 2024 · Analysts like Cingulate more than other Medical companies. The consensus rating score for Cingulate is 3.00 while the average consensus rating score for medical companies is 2.65. Learn more on how CING compares to other companies. What analysts cover Cingulate? WebMar 10, 2024 · 04 Apr 2024 Cingulate Completes First Cohort of Phase 3 Adult Onset and Duration Trial of CTx-1301 (dexmethylphenidate) for ADHD. Trial On Track for 3Q 2024 Results Pivotal Phase 3 Trial in Pediatric/Adolescent Patients Planned to Begin Mid-2024 KANSAS CITY, Kan., April 04, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: … ttrs players
Cingulate Inc. (CING) Company Profile & Overview - Stock Analysis
WebSep 30, 2024 · Pavel_Chag/iStock via Getty Images. Quick Take. Cingulate (NASDAQ:CING) intends to raise $50 million from the sale of its common stock in an IPO, according to an amended registration statement.The ... WebSynonyms for cingulate in Free Thesaurus. Antonyms for cingulate. 7 words related to cingulum: anatomical structure, bodily structure, body structure, complex body part, … WebFind the latest Cingulate Inc. (CINGW) stock quote, history, news and other vital information to help you with your stock trading and investing. ttrs red nose day 2022